Answered raw tape
D 5 · C 5 · P 4 · Cm 4 4.60
Q sort of beyond where, where they are now. Um, what, what do you think it could be, or, or I'm curious to get your take on what do you think is going to be the technological breakthrough that we're going to point back to and say, oh, this is really what, what said it all that, or do you think it's going to be sort of, you know, multi-factor combination?
A Yeah, I look, I think, um, it's, it's going to go back to, uh, sort of where we started, uh, this combination, uh, conversation, excuse me, uh, GLP ones, uh, as a drug are, you know, what, four decades in the making or something like that. You know, these are, these are not overnight successes. Um, uh, but I do think what we are going to see more of, and our hope is that when you combine the fact that we're getting better at, uh, understanding what to target, Getting better at designing medicines to hit those targets, by the way, in a whole array of new creative ways. So we have small molecules, the natural products that we got from boiling leaves, as you said earlier, like those have gotten, you know, we're getting really good at designing smarter and better, smaller molecules, small molecules that do new things that function in ways that they didn't before. Um, we've gotten quite good at designing, uh, biologics or proteins with a lot of help from things like alpha fold that helps understand how proteins fold. We're going to get a lot better at designing some of the more complex modalities like the gene therapies of the world or the gene editors of the world. And when you can do that and combine that with our ability to hopefully use things like virtual cell models to really understand what to go after, like we're going to have drugs. We, I would hope and I would expect that …
AI assessment note: “I think, um, it's, it's going to go back to, uh, sort of where we started”
Answered raw tape
D 5 · C 5 · P 4 · Cm 4 4.60
Q sort of beyond where, where they are now. Um, what, what do you think it could be, or, or I'm curious to get your take on what do you think is going to be the technological breakthrough that we're going to point back to and say, oh, this is really what, what said it all that, or do you think it's going to be sort of, you know, multi-factor combination?
A Yeah, I look, I think, um, it's, it's going to go back to, uh, sort of where we started, uh, this combination, uh, conversation, excuse me, uh, GLP ones, uh, as a drug are, you know, what, four decades in the making or something like that. You know, these are, these are not overnight successes. Um, uh, but I do think what we are going to see more of, and our hope is that when you combine the fact that we're getting better at, uh, understanding what to target, Getting better at designing medicines to hit those targets, by the way, in a whole array of new creative ways. So we have small molecules, the natural products that we got from boiling leaves, as you said earlier, like those have gotten, you know, we're getting really good at designing smarter and better, smaller molecules, small molecules that do new things that function in ways that they didn't before. Um, we've gotten quite good at designing, uh, biologics or proteins with a lot of help from things like alpha fold that helps understand how proteins fold. We're going to get a lot better at designing some of the more complex modalities like the gene therapies of the world or the gene editors of the world. And when you can do that and combine that with our ability to hopefully use things like virtual cell models to really understand what to go after, like we're going to have drugs. We, I would hope and I would expect that …
AI assessment note: “when you combine the fact that we're getting better at, uh, understanding what to target”
